Can Mounjaro Not Work — and Why Progress Sometimes Stalls

Is it normal for Mounjaro to seem like it's not doing anything at first?

Yes, and it is worth understanding why before drawing conclusions. Tirzepatide's licensed schedule begins at 2.5 mg, a dose whose job is to let the body adjust to a new class of medicine, not to produce the weight loss seen at higher strengths. Many people notice very little on those early pens, which is by design. How long Mounjaro takes to work depends partly on which dose you are currently at, and most clinicians would not assess effectiveness until a patient has spent meaningful time at 10 mg or above.

The mechanism also takes time to express itself fully. Tirzepatide works by activating both GIP and GLP-1 receptors, slowing gastric emptying and signalling satiety, but appetite change is not a switch. It builds over weeks. Some people notice a clear reduction in hunger from the first pen; others reach 10 mg before that shift becomes obvious. The NHS's medicines information for tirzepatide notes that the graduated titration schedule exists precisely to manage tolerability, and skipping or rushing doses often makes side effects worse without speeding up results.

Tracking weight daily can also be misleading. Body weight fluctuates by up to two or three kilograms across a single week because of water retention, digestive timing, and hormonal cycles. Weighing once a week, same time and conditions, gives a cleaner picture of trend than daily variation.

What else can stop Mounjaro working as expected?

Biology plays the largest role, but several external factors consistently show up when people are not seeing expected progress. Diet is the most common one. Mounjaro reduces appetite strongly in most people, but it does not rewrite what the body does with calories consumed. Ultra-processed foods, calorie-dense drinks, and irregular eating patterns can collectively offset what the medicine is doing, not because the medicine has stopped working, but because energy balance still matters alongside it.

Sleep and stress are less obvious but relevant. Chronic poor sleep raises cortisol and disrupts appetite-regulating hormones independently of any medicine, and stress eating can override the satiety signals tirzepatide creates. A few people are surprised to find that weight loss accelerates once they address sleep, not just food.

Certain other medicines can interact. Oral contraceptives, some antidepressants, steroids and antipsychotics are among the classes that can affect weight independently. Anyone on a complex medication list should have that reviewed alongside tirzepatide treatment; there are people for whom Mounjaro is not appropriate, and a prescriber can identify factors that might limit its effect before treatment starts.

Physical activity is frequently underestimated. Tirzepatide preserves more lean muscle than aggressive calorie restriction alone, but that advantage requires activity to convert into maintained metabolic rate. Muscle loss during weight loss is one reason metabolic rate can drop; resistance training in particular helps prevent it.

Could it simply not work for me, even if I do everything right?

It is an honest question, and the honest answer is: for a small proportion of people, the response to tirzepatide is genuinely lower than average. The SURMOUNT-1 trial (which enrolled thousands of adults and reported average weight loss of around 20–21% at 15 mg) showed a clear distribution of outcomes, not a single result. A minority of participants lost considerably less. Genetics, gut microbiome differences, insulin resistance patterns and baseline metabolic rate all influence individual response in ways that are still being studied.

If you have been at the highest tolerated dose for several months and the scales have not moved, that is a conversation to have with a prescriber, not a reason to stop treatment unilaterally. Sometimes the picture changes at a higher dose; sometimes a broader clinical review surfaces something that had been missed. Why Mounjaro might not be working for a particular person often has a specific, addressable reason.

Cost is sometimes a barrier to staying at the right dose. If that is part of the picture, how Mounjaro is priced in the UK and what to look for in a service is worth understanding before making any decisions. The short version: treatment cost varies by provider and dose; a service that includes clinical review at every stage is worth more than the headline number suggests.

When should I contact a prescriber rather than just waiting it out?

Waiting is reasonable in the first few months, and especially during dose titration. But there are situations that need prompt clinical attention rather than patience. If weight has been completely static for three or more months at the highest tolerated dose, a clinical review (not just a repeat prescription) is appropriate. There can be underlying reasons worth ruling out: thyroid function, polycystic ovary syndrome and cortisol abnormalities are all conditions that can limit weight-loss response independently of the medicine.

Side effects that are making it impossible to eat properly are a different kind of problem. Persistent nausea or reflux affecting nutrition is worth raising with your prescriber well before the three-month mark. Similarly, if you have developed any new medical condition or started a new medication since beginning tirzepatide, that changes the clinical picture and should be flagged.

For anyone who has already been through one course and is wondering whether Mounjaro works as well the second time, the evidence suggests the mechanism itself remains intact, response the second time tends to mirror the first, provided the same clinical conditions apply.

Our prescribers at nume review every consultation personally, there is no automated decision sitting behind your care. If you are at a stage where you want a fresh clinical pair of eyes on whether this treatment is right for you, check your eligibility through a free consultation.